Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials
Aditxt, Inc. (NASDAQ: ADTX) announced the commencement of GMP manufacturing for its drug candidate ADI™-100 under the Adimune™ program, aiming to start first-in-human trials in the second half of 2023, pending regulatory approvals. Targeting autoimmune diseases, it will initially focus on psoriasis. Previous toxicology studies confirm ADI™-100's safety. The global psoriasis treatment market is projected to grow from $26.37 billion in 2022 to $47.24 billion by 2029, reflecting a strong potential for Adimune’s innovative approach that restores immune tolerance rather than suppressing it.
- Initiation of GMP manufacturing for ADI™-100 marks a key milestone.
- Potential to begin first-in-human trials in the second half of 2023.
- Encouraging toxicology results confirm safety for ADI™-100.
- Target market for psoriasis treatment projected to grow significantly from $26.37 billion in 2022 to $47.24 billion by 2029.
- ADI™ technology offers a novel approach by restoring immune tolerance.
- None.
Dr.
Psoriasis, caused when the immune system attacks skin cells, triggers chronic production of itchy, inflamed, thick scaly skin patches that can be very painful. Treatments currently range from creams and ointments to ultraviolet light therapy to drugs. Many of those suffering with psoriasis also have serious health conditions such as diabetes, heart disease and depression. Some psoriasis sufferers also have an inflammatory condition called psoriatic arthritis that affects their joints.
Adimune’s™ solution aims to prevent the immune system attacks by restoring immune tolerance and addressing the root cause of skin cell build-ups. Treatment with ADI™-100 reduced skin thickening by
“The impact of Adimune’s™ approach to treating autoimmune disease may have a game changing impact in a worldwide market estimated at more than 1.2 million Type 1 diabetes patients under the age of 20 and another 125 million psoriasis patients,” said
“Aditxt’s vision is dedicated to a new era of precision medicine through individual immune monitoring and modulation,” said
The global psoriasis treatment market size is projected to grow from
Adimune™ is planning to develop the ADI™ technology platform to address a wide variety of indications.
About
For more information, please visit: www.Aditxt.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20221021005096/en/
Media and Investor Relations Contact:
ir@aditxt.com
www.aditxt.com
Source:
FAQ
What is Aditxt's recent press release about ADI™-100?
When does Aditxt plan to begin human trials for ADI™-100?
What does Aditxt's ADI™ technology aim to achieve?